With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug
When Pliant Therapeutics bagged its $62 million B round almost two years ago, CEO Bernard Coulie positioned its lead program in idiopathic pulmonary fibrosis right behind Biogen, which he sees as a frontrunner 18 months ahead.
Coming into the Series C, that’s no longer the case. Biogen scrapped its Phase II trial last September due to safety concerns, leaving Pliant even more room to make a splash with the mid-stage programs it now plans to run with $100 million of new cash in the bank.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.